Prolia (denosumab) is a fully human monoclonal antibody that specifically binds to and inhibits the receptor activator of NF-kappaB ligand (RANK Ligand), the primary mediator of bone resorption. RANK Ligand is the protein responsible for activating osteoclasts, the cells that break down bone. An increased amount of the protein has been linked as the primary cause of a broad range of bone loss conditions including osteoporosis, treatment-induced bone loss, bone erosions in rheumatoid arthritis (RA), and bone metastases.Prolia is specifically indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Prolia is supplied as a solution for subcutaneous administration. The recommended initial dose is 60 mg administered as a single subcutaneous injection once every 6 months. Prolia should be administered via subcutaneous injection in the upper arm, the upper thigh, or the abdomen.
The FDA approval of Prolia for the treatment of postmenopausal osteoporosis was based on a 3-year, randomized, double-blind, placebo-controlled trial. The trial enrolled 7,808 women aged 60 to 91 years with a baseline BMD T-score between -2.5 and -4.0 at either the lumbar spine or total hip. Women with other diseases or on therapy that affect bone were excluded. The Women were randomized to receive SC injections of either placebo or Prolia 60 mg once every 6 months. All women received at least 1000 mg calcium and 400 IU vitamin D supplementation daily.The primary efficacy endpoint as the incidence of new morphometric (radiologically-diagnosed) vertebral fractures at 3 years.
Effect on vertebral fractures:
Prolia significantly reduced the incidence of new morphometric vertebral fractures at 1, 2, and 3 years (p < 0.0001). The incidence of new vertebral fractures at year 3 was 7.2% in the placebo-treated women compared to 2.3% for the Prolia-treated women.
Effect on hip fractures
The incidence of hip fracture was 1.2% for placebo-treated women compared to 0.7% for Prolia-treated women at year 3.
Effect on nonvertebral fractures
Treatment with Prolia resulted in a significant reduction in the incidence of nonvertebral fractures: 8.0% in the placebo arm versus 6.5% in the Prolia arm.
Effect on bone mineral density (BMD)
Treatment with Prolia significantly increased BMD at all anatomic sites measured at 3 years. The treatment differences in BMD at 3 years were 8.8% at the lumbar spine, 6.4% at the total hip, and 5.2% at the femoral neck. BMD returned to approximately baseline levels within 12 months after discontinuation of Prolia therapy.
Adverse events associated with the use of Prolia may include, but are not limited to, the following:
Prolia (denosumab) is a fully human monoclonal antibody that binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.
For additional information regarding Prolia or osteoporosis and menopause related bone loss, please visit the Prolia web page.
The Prolia (denosumab) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.